Jingdong Xie

机构：Daiichi Sankyo (United States)

发表论文 20 篇 · 总被引 177 次 · h-index 5

代表论文

• Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: A systematic review and meta-analysis (2013 · Gene · 被引 54)
• TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC (2023 · Future Oncology · 被引 48)
• Association of IL 28B polymorphisms with peginterferon treatment response in Chinese Han patients with HB eAg‐positive chronic hepatitis B (2014 · Liver International · 被引 26)
• Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma (2022 · Clinical and Experimental Medicine · 被引 12)
• Serum keratin‐18 fragments as cell death biomarker in association with disease progression and prognosis in hepatitis B virus‐related cirrhosis (2019 · Journal of Viral Hepatitis · 被引 11)
• Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations. (2022 · Journal of Clinical Oncology · 被引 5)